Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 17/20 | 0.79 |
| ▸ | CTSG | P08311 | 5/20 | 0.54 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.45 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8113055 | 1.00 | CMA1 (0.79) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL2312625 | 0.89 | CMA1 (1.00) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL8113260 | 0.86 | CMA1 (0.58) | CMA1CTSGKMT2A | |
| SCHEMBL2311537 | 0.84 | CMA1 (0.74) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL2313128 | 0.84 | CMA1 (0.74) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL2318188 | 0.83 | CMA1 (0.71) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL2310335 | 0.81 | CMA1 (0.84) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL2310271 | 0.80 | CMA1 (0.79) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL2312014 | 0.80 | CMA1 (0.67) | CMA1CTSGSLC12A2KMT2ASLC12A5 | |
| SCHEMBL2311834 | 0.80 | CMA1 (0.67) | CMA1CTSGSLC12A2KMT2ASLC12A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008147697-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |